Life Extension Magazine®

Issue: Oct 2006

Homocysteine as a Risk Factor for Disease

A summary of 16 years of landmark research shows that excess homocysteine is linked to a surprisingly wide variety of aging-related disorders, including cancer, depression, Alzheimer’s disease, osteoporosis, macular degeneration, and, of course, vascular diseases.

By Laura J. Ninger, ELS.

Since 1990, the National Library of Medicine has posted thousands of scientific studies showing that homocysteine is a significant risk factor for disease.1

These published reports discuss the lethal illnesses associated with excess homocysteine, how elevations in blood homocysteine levels result in incremental increases in disease risks, the mechanisms by which homocysteine exerts its multiple pathological effects, and methods to reduce toxic homocysteine levels in the body.

Elevated homocysteine levels may be caused by B-vitamin deficiency, genetic factors, increasing age, kidney impairment, or other factors. Homocysteine overload increases the risk of disease in healthy people and magnifies adverse effects in those with pre-existing conditions.

Since 1981, the Life Extension Foundation has published hundreds of pages of text describing the dangers of excess homocysteine in the blood. What follows is a brief chronological review of landmark studies published in major medical journals that describe specific disease risks associated with excess homocysteine.


Cardiovascular Disease: Researchers found that men with premature coronary artery disease (who averaged 50 years of age) had significantly higher homocysteine levels than healthy men. Scientists thus determined that high levels of homocysteine are an independent risk factor for premature coronary atherosclerosis in men.1


Early-Onset Vascular Disease: Higher levels of homocysteine raise the risk of premature cardiovascular disease affecting the heart, brain, and peripheral blood vessels. In subjects who developed cardiovascular disease before the age of 55, elevated blood levels of homocysteine were found in 42% of patients with cerebrovascular disease, 30% with coronary vascular disease, and 28% with peripheral vascular disease—but not in any of the healthy control subjects. People with elevated homocysteine had three times the risk of cardiovascular disease compared to healthy individuals.2

Cardiovascular Disease Progression: Patients with blocked arteries in the lower body or brain were found to have significantly higher homocysteine levels than healthy individuals. In addition, patients with high homocysteine (versus normal levels) had significantly faster progression of lower-extremity vascular disease and coronary artery disease.3


Heart Attack: In a large study, men who had markedly higher homocysteine levels had over three times the risk of heart attack compared to men with lower homocysteine values.4

Stroke: Elevated homocysteine levels were independently associated with all types of stroke (ischemic, hemorrhagic, and embolic). Stroke survivors were more likely to demonstrate elevated homocysteine levels (40%) than healthy individuals (6%).5


Blood Clotting: High homocysteine levels have been linked with increased blood-clotting tendency. In the laboratory, homocysteine increased the activity of a blood-clotting factor in human cells by 25-100%, and this negative effect increased with rising homocysteine concentrations.6 In a similar study, homocysteine decreased the production of a substance that helps prevent blood clots by 65%.7


Early-Onset Coronary Artery Disease: Noting that high homocysteine raises the risk of early-onset coronary artery disease, scientists proposed that boosting plasma folate concentration may help reduce homocysteine levels and decrease coronary artery disease risk.8


Atherosclerosis: In elderly adults, dangerous narrowing of the arteries that direct blood to the brain was more than twice as common in those with higher homocysteine levels (greater than 14.4 μmol/L) than in those with low levels (less than 9.1 μmol/L).9 Another study found that individuals with high homocysteine were much more likely to have atherosclerosis (72%) than those with normal homocysteine (44%).10 In patients already at risk for atherosclerosis because of high lipid levels, elevated homocysteine further increased the risk by nearly three times.10

Coronary Artery Disease: High homocysteine was found to be an independent risk factor for coronary artery disease among healthy people. Each 4-μmol/L increase in homocysteine level increased risk by 32%.11

Birth Defects: Abnormal homocysteine metabolism may be associated with birth defects that affect the coverings of the nervous system (neural tube defects).12 Elevated homocysteine levels have been found in the amniotic fluid of fetuses with neural tube defects and in blood samples of women carrying fetuses with these birth defects.12,13 Folic acid supplements may help prevent such birth defects by correcting high homocysteine levels.12,13


Pediatric Atherosclerosis: In boys and girls aged 10-19, elevated homocysteine levels were significantly associated with atherosclerosis in the carotid arteries, which supply the brain with blood. This suggests that homocysteine levels correlate with atherosclerosis, even as early as in the second decade of life.14

Cardiovascular Disease: In another pediatric study, homocysteine levels were significantly higher among children who had a male relative who died prematurely (under 55 years of age) of heart attack. Nutritional modifications may help reduce cardiovascular risk in children with a family history of heart disease.15

Coronary Artery Disease: Scientists discovered that one of the causes of elevated homocysteine levels is a particular genetic mutation, and that people with this mutation had a significantly higher risk of premature coronary heart disease.16

Birth Defects: Scientists again noted that homocysteine levels are significantly higher in women with fetuses that have neural tube birth defects than in those with healthy fetuses, further supporting the theory that folic acid supplementation may help prevent birth defects by improving homocysteine metabolism.17


Atherosclerosis: Scientists found that elevated homocysteine was just as serious a risk factor for atherosclerosis as smoking or high lipid levels, and that it dramatically aggravated the risk associated with smoking or high blood pressure.18 In one study, every 5-μmol/L increase in homocysteine level led to a 30% increased risk of severe atherosclerosis.19 In addition, researchers found that people with higher levels of homocysteine had more blocked arteries than people with lower homocysteine levels.19

Death from Coronary Artery Disease: Higher homocysteine levels strongly predict mortality risk in people with coronary heart disease. People with homocysteine levels above 15 μmol/L had a 25% mortality rate over four years, compared to only 4% for those who had homocysteine levels below 9 μmol/L. Death rates rose dramatically as homocysteine levels rose from 9 to 20 μmol/L.20


Cardiovascular Disease and Stroke: High levels of homocysteine increase the risk of diseased arteries of the extremities, heart, and brain.21,22 One study suggested that every 5-μmol/L increase in homocysteine level increases the risk of peripheral vascular disease by 44%, coronary artery disease by 25%, cerebrovascular disease by 24%, and any cardiovascular disease by 39%.21 In people who have type II diabetes or impaired glucose tolerance, elevated homocysteine poses even greater dangers to the cardiovascular system.21 In one study, elderly men with high homocysteine had almost twice the risk of heart attack and more than four times the risk of stroke, as well as six times the risk of fatal stroke.23

Ischemic Heart Disease: Men with higher homocysteine levels were up to three times more likely to die of ischemic heart disease—caused by a diminished supply of blood and oxygen to the heart muscle—than those who had lower levels. This correlation was so strong that scientists proposed that elevated homocysteine might actually cause heart disease, rather than simply be a risk factor for it.24


Cardiovascular Disease: Homocysteine damages endothelial cells, promotes blood clots, and supports free radical damage.25 Homocysteine is associated with risks in both adults and children. In fact, healthy children with higher homocysteine levels were more likely to have increased blood pressure compared to their peers with normal homocysteine. These children have a higher risk for future cardiovascular disease.26 Testing blood homocysteine levels in children may help to identify those with a high level of heart disease risk, so that preventive strategies can be started as soon as possible.26

Colon Cancer: Women with higher homocysteine had a higher risk of colorectal cancer than women with lower levels. Those with the highest homocysteine levels had a more than 70% higher colorectal cancer risk than those with the lowest values. This led scientists to suggest that vitamin supplementation strategies to lower homocysteine levels might also decrease colorectal cancer risk.27

Birth Defects: Because high homocysteine levels are associated with both neural tube birth defects and heart disease, scientists proposed that disturbances in homocysteine breakdown might underlie both conditions. By supporting homocysteine breakdown, folic acid supplements might help prevent birth defects as well as heart disease.28


Atherosclerosis: Elevated homocysteine is associated with an increased risk of atherosclerosis, heart attack, and heart disease mortality.29 Elevated homocysteine levels are strongly associated with severe atherosclerosis in one of the body’s main blood vessels, the aorta.30

Kidney and Heart Disease: In patients with early- or end-stage kidney disease, elevated homocysteine is an independent predictor of cardiovascular disease.31

Cervical Cancer: Elevated homocysteine levels may increase the risk of cervical cancer. One study found that women who had a precursor to cervical cancer had higher homocysteine levels than healthy subjects. High homocysteine also increased the cervical cancer risk associated with smoking, having several previous births, and infection with a virus associated with cervical cancer. Elevated homocysteine increases the risk of cervical tissue changes that can lead to cancer, and enhances the effects of other risk factors.32

Depression: Scientists noted that 52% of patients with severe depression had elevated homocysteine levels, as well as decreased levels of folate and impaired metabolism of certain neurotransmitters. A significant correlation between elevated homocysteine and decreased folate concentrations was noted in depressed people. Scientists thus proposed that measuring homocysteine levels may help identify people with depression, and that homocysteine-lowering therapies might elevate mood.33

Pregnancy Complications: Elevated homocysteine levels may increase the risk of several complications of pregnancy. In a large study, scientists found that pregnant women with the highest homocysteine levels had an increased risk of premature births, low-birth-weight infants, and stillbirths.34


Alzheimer’s Disease: Elevated homocysteine levels may contribute to cognitive decline and Alzheimer’s disease.35,36 In healthy older adults, high homocysteine was associated with poorer cognitive function and faster cognitive decline over the course of five years.36 Although scientists do not know whether homocysteine causes cognitive decline or Alzheimer’s, they have noted that high homocysteine correlates with the progression and severity of these conditions.35

Invasive Cervical Cancer: Homocysteine may increase the risk for cervical cancer. Researchers found that women with elevated homocysteine levels were two to three times more likely to have invasive cervical cancer.37

Coronary Artery Disease: Since 1998, grain products in the United States have been fortified with folic acid to promote good health. By lowering homocysteine levels, grain fortification could reduce heart attacks and heart disease deaths by 8% in women and 13% in men. This strategy may save several hundred thousand lives and several billion dollars in health care costs over the course of 10 years, according to one analysis.38

Blood Clots: One study found that when homocysteine levels are high, the risk of dangerous blood clots (deep vein thrombosis) more than doubled. Blood clots are potentially lethal, since they can lead to heart attack or stroke.39

Overall Mortality: Elevated homocysteine increases the risk of death due to cancer and other causes. A 2001 study showed that each 5-μmol/L increase in homocysteine was associated with a 26% increase in cancer deaths, a 49% increase in all-cause mortality, a 50% increase in cardiovascular deaths, and a 104% increase in deaths not due to cancer or cardiovascular disease. Managing homocysteine levels may thus be crucial to prolonging life and preventing death from numerous health conditions.40


Alzheimer’s Disease: Rising levels of homocysteine could be an early warning signal of impending dementia and Alzheimer’s in elderly men and women. High homocysteine (greater than 14 μmol/L) almost doubled the risk of Alzheimer’s disease, suggesting a possible cause-and-effect relationship between homocysteine and Alzhiemer’s.41

Cardiovascular Disease: High homocysteine levels make the cardiovascular risks of smoking even more dangerous. In one study, smokers with high homocysteine levels had 12 times the risk of cardiovascular disease compared to nonsmokers with normal homocysteine.42

Ischemic Heart Disease and Stroke: Lowering homocysteine levels may decrease the risk of heart disease and stroke.43-45 Studies have suggested that lowering one’s homocysteine level by 3 μmol/L could decrease the risk of ischemic heart disease by 11-16%, while decreasing the risk of stroke by 19-24%.43,44


Dementia: Because elevated homocysteine plays a role in stroke and Alzheimer’s disease—two major causes of dementia—researchers proposed that dietary supplementation to normalize homocysteine levels could reduce rates of dementia.46

Cognitive Impairment: Healthy people who wish to maintain their cognitive function should monitor their homocysteine levels. Over the course of six years, healthy individuals with high homocysteine levels at the study’s onset had much poorer scores on word-learning tests than their counterparts with low homocysteine levels.47

Inflammatory Bowel Disease: High levels of homocysteine in the colon and blood may predispose individuals to two inflammatory bowel diseases: ulcerative colitis and Crohn’s disease. Homocysteine levels were significantly elevated in the colons of patients with inflammatory bowel diseases compared to healthy subjects.48

Ischemic Heart Disease and Stroke: People with high homocysteine levels have a much greater risk of ischemic heart disease and stroke.49 In patients with coronary heart disease, those with the highest homocysteine levels had an almost fivefold greater risk of stroke.50 Some research suggests that lowering homocysteine by 25% may lead to an 11% decrease in ischemic heart disease risk and a 20% decrease in stroke risk.49


Aneurysm: One of the most dangerous manifestations of cardiovascular disease is aortic aneurysm, a bulging of the body’s largest artery that can lead to rupture, a potentially fatal surgical emergency. Researchers found that 68% of adults with abdominal aortic aneurysm had elevated homocysteine levels, compared to only 6% of unaffected individuals. Patients with aneurysm had an average homocysteine level of 19.4 μmol/L, compared to 10.9 μmol/L among unaffected adults.51

Cardiovascular Disease: About half of all deaths occur because of cardiovascular disease, and elevated homocysteine may contribute to 10% of cardiovascular disease cases and deaths.52 Cardiovascular disease risk grows as homocysteine increases, and the risk is especially high in people with high blood pressure, diabetes, or high lipid levels.52 Homocysteine damages blood vessels, promotes blood clotting, and generates oxidative stress.52 Some experts estimate that lowering homocysteine could prevent 25% of cardiovascular events,52 and some recommend that all individuals at risk for heart disease should be treated regardless of their baseline homocysteine values.53 Homocysteine poses risks to men, women, and children, and particularly to people with underlying illnesses.54-56

Cognitive Impairment: High levels of homocysteine are associated with detrimental changes in the nervous system that can be detected using radiological imaging57 or clinical assessments.58 In one study, people with the highest homocysteine levels had lower scores on cognitive function tests. High homocysteine levels were also associated with a 4.3 times higher risk of dementia and a 3.7 times greater risk of Alzheimer’s disease.58

Osteoporosis: Elevated homocysteine levels may increase the risk of osteoporotic fractures in older men and women.59,60 In one report, the risk of hip fracture increased with rising levels of homocysteine in both sexes.59 Men with the highest levels had about four times the risk of fracture as men with the lowest levels, and women with the highest values had twice the risk as those with the lowest levels.59 Lowering homocysteine levels using nutritional strategies may thus help protect bone health.59


Alzheimer’s Disease: Rising levels of homocysteine may predict impending cognitive decline and Alzheimer’s disease.61,62 In one study, high levels of homocysteine were associated with worse cognitive function, and elevated homocysteine predicted more severe cognitive decline during seven years of follow-up.61 Moreover, elevated homocysteine was associated with a three times higher risk of Alzheimer’s disease and a 2.6 times higher risk of mild cognitive impairment, which typically precedes more severe dementia.62

Aneurysm: People who have high homocysteine levels may have an eightfold greater risk of abdominal aortic aneurysm. When an aneurysm ruptures, fatal bleeding can occur unless the patient receives prompt surgical care.63

Atherosclerosis: Elevated homocysteine may speed the progression of atherosclerosis. One study showed that atherosclerosis progressed by 35% annually for patients with high homocysteine levels (greater than or equal to 12 μmol/L), but by only 17% per year in people with lower levels (less than 12 μmol/L).64

Cardiovascular Disease: When researchers followed healthy men for 10 years, they noticed that the men with the highest homocysteine levels had nearly twice the risk of cardiovascular disease death.65 Homocysteine was even more dangerous in smokers and in men with high cholesterol.65 In healthy women, increased homocysteine levels were associated with decreased oxygen uptake, indicating poorer cardiovascular fitness.66

Cognitive Impairment: Homocysteine may interfere with healthy mental function.67-69 In one report, healthy elderly people with high homocysteine levels experienced more dramatic cognitive decline over six years than did their counterparts with lower homocysteine levels.68 One study suggested that homocysteine may prematurely age the brain. A rise in homocysteine was equivalent to an extra 4.2 years of age on cognitive performance tests. Homocysteine might thus be a modifiable cause of cognitive decline.69

Depression: Depression and high homocysteine appear to be closely related. In people aged 60-64, a higher homocysteine level was associated with a higher prevalence of depression.70

Macular Degeneration: Homocysteine may damage eye health and threaten visual function. In fact, scientists found that patients with age-related macular degeneration had significantly higher homocysteine levels than healthy subjects.71,72

Bipolar Disorder: Homocysteine may be associated with bipolar (manic depressive) disorder. One study showed that young men with bipolar disorder had much higher homocysteine levels than healthy subjects, and homocysteine levels were highest in those with progression of the disease.73

Osteoporosis: Elevated homocysteine may adversely affect bone health and fracture risk.74 In healthy adults, high homocysteine was associated with 3.8 times the risk of fracture in men and 2.8 times the risk in women.75 Scientists believe that elevated homocysteine could be a clinical sign of osteoporosis related to nutritional deficiencies.74 High homocysteine may especially increase the risk of fractures in people suffering from underlying illnesses, such as Parkinson’s disease or a history of stroke.76,77

Schizophrenia: Some scientists believe that schizophrenia begins even before birth. Pregnant women with high levels of homocysteine were found to be more likely to have children who later developed schizophrenia. Researchers believe this may be one more reason why pregnant women should take steps to correct elevated homocysteine levels.78

Stroke: Over the course of 10 years, men with high homocysteine levels had nearly three times the risk of stroke as men with low levels of homocysteine. High serum folate levels, however, were associated with protection against stroke.79


Coronary Artery Disease: People with elevated levels of homocysteine were found to have more calcification of the coronary arteries than people with lower homocysteine values. Coronary artery calcification is a measure of the severity of coronary artery disease.80

Kidney Disease: Patients with chronic kidney disease were found to have significantly higher levels of homocysteine than healthy people. In fact, 89% of these patients had homocysteine levels greater than 14 μmol/L, which may increase their risk of developing many other diseases.81

Macular Degeneration: Patients with age-related macular degeneration, a common cause of visual loss, were found to have higher homocysteine levels than healthy subjects. Levels above 12 μmol/L particularly increased the risk of macular degeneration. High homocysteine level may thus be an independent risk factor for age-related macular degeneration.82

Osteoporosis: Women with high homocysteine levels were found to have significantly lower bone mineral density in the hip than control subjects. In fact, the risk of low bone density was 96% higher among women with high homocysteine (greater than 15 μmol/L) compared to women with lower homocysteine (less than 9 μmol/L). Homocysteine may be a modifiable risk factor for osteoporosis in women.83

Schizophrenia: Homocysteine levels are extremely high in many patients with schizophrenia. When these individuals used vitamins to decrease homocysteine, their symptoms of schizophrenia lessened.84


Elevated homocysteine levels have now been correlated with a wide array of illnesses, including heart disease, stroke, osteoporosis, depression, schizophrenia, macular degeneration, cervical cancer, and birth defects.

Fortunately, those seeking to safeguard their health and longevity can readily modulate elevated homocysteine levels using nutritional therapies such as vitamins B6 and B12, folic acid, and trimethylglycine.85 These important nutritional strategies may help you avert the wide array of diseases that have been found to accompany excessive levels of homocysteine.


1. Genest JJ, Jr., McNamara JR, Salem DN, et al. Plasma homocyst(e)ine levels in men with premature coronary artery disease. J Am Coll Cardiol. 1990 Nov;16(5):1114-9.

2. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med. 1991 Apr 25;324(17):1149-55.

3. Taylor LM, Jr., DeFrang RD, Harris EJ, Jr., Porter JM. The association of elevated plasma homocyst(e)ine with progression of symptomatic peripheral arterial disease. J Vasc Surg. 1991 Jan;13(1):128-36.

4. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992 Aug 19;268(7):877-81.

5. Brattstrom L, Lindgren A, Israelsson B, et al. Hyperhomocysteinaemia in stroke: prevalence, cause, and relationships to type of stroke and stroke risk factors. Eur J Clin Invest. 1992 Mar;22(3):214-21.

6. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb. 1993 Sep;13(9):1327-33.

7. Hajjar KA. Homocysteine-induced modulation of tissue plasminogen activator binding to its endothelial cell membrane receptor. J Clin Invest. 1993 Jun;91(6):2873-9.

8. Pancharuniti N, Lewis CA, Sauberlich HE, et al. Plasma homocyst(e)ine, folate, and vitamin B-12 concentrations and risk for early-onset coronary artery disease. Am J Clin Nutr. 1994 Apr;59(4):940-8.

9. Selhub J, Jacques PF, Bostom AG, et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995 Feb 2;332(5):286-91.

10. Glueck CJ, Shaw P, Lang JE, et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol. 1995 Jan 15;75(2):132-6.

11. Arnesen E, Refsum H, Bonaa KH, et al. Serum total homocysteine and coronary heart disease. Int J Epidemiol. 1995 Aug;24(4):704-9.

12. Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet. 1995 Jan 21;345(8943):149-51.

13. Steegers-Theunissen RP, Boers GH, Blom HJ, et al. Neural tube defects and elevated homocysteine levels in amniotic fluid. Am J Obstet Gynecol. 1995 May;172(5):1436-41.

14. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):984-91.

15. Tonstad S, Refsum H, Sivertsen M, et al. Relation of total homocysteine and lipid levels in children to premature cardiovascular death in male relatives. Pediatr Res. 1996 Jul;40(1):47-52.

16. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation. 1996 Nov 1;94(9):2154-8.

17. Mills JL, Scott JM, Kirke PN, et al. Homocysteine and neural tube defects. J Nutr. 1996 Mar;126(3):756S-60S.

18. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997 Jun 11;277(22):1775-81.

19. Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 1997 May;17(5):989-95.

20. Nygard O, Nordrehaug JE, Refsum H, et al. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997 Jul 24;337(4):230-6.

21. Hoogeveen EK, Kostense PJ, Beks PJ, et al. Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol. 1998 Jan;18(1):133-8.

22. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62.

23. Stehouwer CD, Weijenberg MP, van den BM, et al. Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol. 1998 Dec;18(12):1895-901.

24. Wald NJ, Watt HC, Law MR, et al. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med. 1998 Apr 27;158(8):862-7.

25. Scott CH, Sutton MS. Homocysteine: evidence for a causal relationship with cardiovascular disease. Cardiol Rev. 1999 Mar;7(2):101-7.

26. Osganian SK, Stampfer MJ, Spiegelman D, et al. Distribution of and factors associated with serum homocysteine levels in children: Child and Adolescent Trial for Cardiovascular Health. JAMA. 1999 Apr 7;281(13):1189-96.

27. Kato I, Dnistrian AM, Schwartz M, et al. Serum folate, homocysteine and colorectal cancer risk in women: a nested case-control study. Br J Cancer. 1999 Apr;79(11-12):1917-22.

28. Stone DH, McCarron P, Smith GD. Similarities in the epidemiology of neural tube defects and coronary heart disease: is homocysteine the missing link? J Epidemiol Community Health. 1999 Dec;53(12):789-93.

29. Temple ME, Luzier AB, Kazierad DJ. Homocysteine as a risk factor for atherosclerosis. Ann Pharmacother. 2000 Jan;34(1):57-65.

30. Tribouilloy CM, Peltier M, Iannetta Peltier MC, et al. Plasma homocysteine and severity of thoracic aortic atherosclerosis. Chest. 2000 Dec;118(6):1685-9.

31. van GC, Robinson K. Homocysteine and renal disease. Semin Thromb Hemost. 2000;26(3):313-24.

32. Thomson SW, Heimburger DC, Cornwell PE, et al. Effect of total plasma homocysteine on cervical dysplasia risk. Nutr Cancer. 2000;37(2):128-33.

33. Bottiglieri T, Laundy M, Crellin R, et al. Homocysteine, folate, methylation, and monoamine metabolism in depression. J Neurol Neurosurg Psychiatry. 2000 Aug;69(2):228-32.

34. Vollset SE, Refsum H, Irgens LM, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study. Am J Clin Nutr. 2000 Apr;71(4):962-8.

35. Postiglione A, Milan G, Ruocco A, et al. Plasma folate, vitamin B(12), and total homocysteine and homozygosity for the C677T mutation of the 5,10-methylene tetrahydrofolate reductase gene in patients with Alzheimer’s dementia. A case-control study. Gerontology. 2001 Nov;47(6):324-9.

36. McCaddon A, Hudson P, Davies G, et al. Homocysteine and cognitive decline in healthy elderly. Dement Geriatr Cogn Disord. 2001 Sep;12(5):309-13.

37. Weinstein SJ, Ziegler RG, Selhub J, et al. Elevated serum homocysteine levels and increased risk of invasive cervical cancer in US women. Cancer Causes Control. 2001 May;12(4):317-24.

38. Tice JA, Ross E, Coxson PG, et al. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA. 2001 Aug 22;286(8):936-43.

39. Cattaneo M, Lombardi R, Lecchi A, Bucciarelli P, Mannucci PM. Low plasma levels of vitamin B(6) are independently associated with a heightened risk of deep-vein thrombosis. Circulation. 2001 Nov 13;104(20):2442-6.

40. Vollset SE, Refsum H, Tverdal A, et al. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr. 2001 Jul;74(1):130-6.

41. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer’s disease. N Engl J Med. 2002 Feb 14;346(7):476-83.

42. O’Callaghan P, Meleady R, Fitzgerald T, Graham I. Smoking and plasma homocysteine. Eur Heart J. 2002 Oct;23(20):1580-6.

43. Anon. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002 Oct 23;288(16):2015-22.

44. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002 Nov 23;325(7374):1202.

45. De BA, Verschuren WM, Kromhout D, Kluijtmans LA, Blom HJ. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev. 2002 Dec;54(4):599-618.

46. Morris MS. Homocysteine and Alzheimer’s disease. Lancet Neurol. 2003 Jul;2(7):425-8.

47. Teunissen CE, Blom AH, Van Boxtel MP, et al. Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. J Nutr Health Aging. 2003;7(3):153-9.

48. Morgenstern I, Raijmakers MT, Peters WH, Hoensch H, Kirch W. Homocysteine, cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in patients with inflammatory bowel disease. Dig Dis Sci. 2003 Oct;48(10):2083-90.

49. Clarke R, Lewington S, Landray M. Homocysteine, renal function, and risk of cardiovascular disease. Kidney Int Suppl. 2003 May;(84):S131-3.

50. Tanne D, Haim M, Goldbourt U, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke. 2003 Mar;34(3):632-6.

51. Warsi AA, Davies B, Morris-Stiff G, Hullin D, Lewis MH. Abdominal aortic aneurysm and its correlation to plasma homocysteine, and vitamins. Eur J Vasc Endovasc Surg. 2004 Jan;27(1):75-9.

52. Stanger O, Herrmann W, Pietrzik K, et al. Clinical use and rational management of homocysteine, folic acid, and B vitamins in cardiovascular and thrombotic diseases. Z Kardiol. 2004 Jun;93(6):439-53.

53. Wald DS, Law M, Morris JK. The dose-response relation between serum homocysteine and cardiovascular disease: implications for treatment and screening. Eur J Cardiovasc Prev Rehabil. 2004 Jun;11(3):250-3.

54. Buccianti G, Baragetti I, Bamonti F, et al. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol. 2004 May;17(3):405-10.

55. Zylberstein DE, Bengtsson C, Bjorkelund C, et al. Serum homocysteine in relation to mortality and morbidity from coronary heart disease: a 24-year follow-up of the population study of women in Gothenburg. Circulation. 2004 Feb 10;109(5):601-6.

56. Gillum RF. Distribution of total serum homocysteine and its association with parental history and cardiovascular risk factors at ages 12-16 years: the Third National Health And Nutrition Examination Survey. Ann Epidemiol. 2004 Mar;14(3):229-33.

57. Scott TM, Tucker KL, Bhadelia A, et al. Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiatry. 2004 Nov;12(6):631-8.

58. Quadri P, Fragiacomo C, Pezzati R, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr. 2004 Jul;80(1):114-22.

59. McLean RR, Jacques PF, Selhub J, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004 May 13;350(20):2042-9.

60. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004 May 13;350(20):2033-41.

61. Kado DM, Karlamangla AS, Huang MH, et al. Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med. 2005 Feb;118(2):161-7.

62. Quadri P, Fragiacomo XC, Pezzati R, et al. Homocysteine and B vitamins in mild cognitive impairment and dementia. Clin Chem Lab Med. 2005;43(10):1096-100.

63. Sofi F, Marcucci R, Giusti B, et al. High levels of homocysteine, lipoprotein (a) and plasminogen activator inhibitor-1 are present in patients with abdominal aortic aneurysm. Thromb Haemost. 2005 Nov;94(5):1094-8.

64. Rasouli ML, Nasir K, Blumenthal RS, et al. Plasma homocysteine predicts progression of atherosclerosis. Atherosclerosis. 2005 Jul;181(1):159-65.

65. Virtanen JK, Voutilainen S, Alfthan G, et al. Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. J Intern Med. 2005 Mar;257(3):255-62.

66. Kuo HK, Yen CJ, Bean JF. Levels of homocysteine are inversely associated with cardiovascular fitness in women, but not in men: data from the National Health and Nutrition Examination Survey 1999-2002. J Intern Med. 2005 Oct;258(4):328-35.

67. Robbins MA, Elias MF, Budge MM, Brennan SL, Elias PK. Homocysteine, type 2 diabetes mellitus, and cognitive performance: The Maine-Syracuse Study. Clin Chem Lab Med. 2005;43(10):1101-6.

68. Teunissen CE, Van Boxtel MP, Jolles J, et al. Homocysteine in relation to cognitive performance in pathological and non-pathological conditions. Clin Chem Lab Med. 2005;43(10):1089-95.

69. Schafer JH, Glass TA, Bolla KI, et al. Homocysteine and cognitive function in a population-based study of older adults. J Am Geriatr Soc. 2005 Mar;53(3):381-8.

70. Sachdev PS, Parslow RA, Lux O, et al. Relationship of homocysteine, folic acid and vitamin B12 with depression in a middle-aged community sample. Psychol Med. 2005 Apr;35(4):529-38.

71. Kamburoglu G, Gumus K, Kadayifcilar S, Eldem B. Plasma homocysteine, vitamin B12 and folate levels in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2006 May;244(5):565-9.

72. Nowak M, Swietochowska E, Wielkoszynski T, et al. Homocysteine, vitamin B12, and folic acid in age-related macular degeneration. Eur J Ophthalmol. 2005 Nov;15(6):764-7.

73. Levine J, Sela BA, Osher Y, Belmaker RH. High homocysteine serum levels in young male schizophrenia and bipolar patients and in an animal model. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Sep;29(7):1181-91.

74. Herrmann M, Widmann T, Herrmann W. Homocysteine—a newly recognised risk factor for osteoporosis. Clin Chem Lab Med. 2005;43(10):1111-7.

75. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, et al. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res. 2005 Jun;20(6):921-9.

76. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson’s disease. Am J Med. 2005 Nov;118(11):1250-5.

77. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in stroke patients. Bone. 2005 Apr;36(4):721-6.

78. Picker JD, Coyle JT. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia? Harv Rev Psychiatry. 2005 Jul;13(4):197-205.

79. Virtanen JK, Voutilainen S, Happonen P, et al. Serum homocysteine, folate and risk of stroke: Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. Eur J Cardiovasc Prev Rehabil. 2005 Aug;12(4):369-75.

80. Kullo IJ, Li G, Bielak LF, et al. Association of plasma homocysteine with coronary artery calcification in different categories of coronary heart disease risk. Mayo Clin Proc. 2006 Feb;81(2):177-82.

81. Nerbass FB, Draibe SA, Feiten SF, et al. Homocysteine and its determinants in nondialyzed chronic kidney disease patients. J Am Diet Assoc. 2006 Feb;106(2):267-70.

82. Seddon JM, Gensler G, Klein ML, Milton RC. Evaluation of plasma homocysteine and risk of age-related macular degeneration. Am J Ophthalmol. 2006 Jan;141(1):201-3.

83. Gjesdal CG, Vollset SE, Ueland PM, et al. Plasma total homocysteine level and bone mineral density: the Hordaland Homocysteine Study. Arch Intern Med. 2006 Jan 9;166(1):88-94.

84. Levine J, Stahl Z, Sela BA, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006 Jan 17.

85. Muntjewerff JW, Kahn RS, Blom HJ, den HM. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta-analysis. Mol Psychiatry. 2006 Feb;11(2):143-9.

Subscribe to Life Extension Magazine®

Subscribe Now

Advertise in Life Extension Magazine®

Learn More